Enumeral Biomedical lands a deal

Enumeral Biomedical Holdings, Inc (ENUM) announced today a collaboration with immunotherapy powerhouse Merck (MRK) to interrogate the tumor microenvironment in colorectal cancer tissues obtained directly from patients. The goal is to identify functional cellular responses to immuno-oncology therapies being developed by Merck.

The press release is here: http://finance.yahoo.com/news/enumeral-merck-form-collaboration-predicting-130000581.html